These new products create biologically relevant conditions to shorten cell expansion times.
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the launch of its human AB serum product line to supplement cell culture media and facilitate cell and gene therapy development.
Human AB serum contains many compounds that are vital for cell growth, including growth factors, vitamins, nutrients, trace elements and transport factors. As a result, human AB serum produces biologically relevant conditions that allow many human cell lines to grow at a faster rate. In addition, a smaller percentage of this serum is required than mixed blood type human serum.
“BioIVT collects blood donations from more than 17,000 donors annually at donor centers located throughout the US and in the UK, so we have a strong, vertically integrated supply chain to support this new product portfolio,” said BioIVT Chief Commercial Officer Alan Findlater. “Furthermore, our recent acquisition of Valley Biomedical Products & Services, Inc. is allowing us to generate larger lots with shorter production times. Valley Biomedical has an excellent track record and has provided the pharmaceutical, biotechnology and academic R&D markets with high quality blood products and cell culture sera for the past 25 years.”
BioIVT is offering both plasma-derived and off-the-clot serum collected from healthy, male AB blood type donors. All products are sterile, filtered, and ready for cell culture.
Customers also have the option to heat-inactivate their serum, to deactivate complement and improve lot-to-lot reliability.
All donor units are tested at the collection facility for viral markers in accordance with current US Food and Drug Administration regulations to ensure they are non-reactive prior to use. Additional testing is also available depending on customers’ needs. The final serum product also undergoes extensive quality control testing before release for distribution.